In the 1990s the discovery of prostate-specific antigen (PSA) revolutionized early prostate
cancer detection. Since that time, PSA has become an indispensable marker for diagnosis …

Due to its significant applicability for early detection, risk prediction and follow-up evaluation,
prostate specific antigen (PSA) has revolutionized our ability to treat prostate cancer …

Prostate cancer has the highest tumour incidence in the male population and represents
9.2% of cancer-related deaths. The most commonly used screening technique up to the …

The detection of prostate cancer using a blood test has by many standards changed the face
of the disease. Despite this tremendous success, there are limitations attributed to the use of …

Prostate cancer is the most noncutaneous malignancy diagnosed in men in the USA. The
discovery of prostate-specific antigen (PSA) revolutionized prostate cancer diagnosis and …

Prostate-specific antigen (PSA) is widely used as a biomarker in the detection of prostate
cancer and for decision making regarding treatment options, response to therapy, and …

The detection and treatment of prostate cancer was dramatically altered with the advent of
the prostate-specific antigen (PSA), and its usefulness particularly in following patients after …

The introduction and widespread adoption of PSA has revolutionized the way prostate
cancer is diagnosed and treated. However, the use of PSA has also led to over-diagnosis …

Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been
employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved …

The limitations of PSA as a screening marker for diagnosis and prostate cancer treatment
are well known. The low specificity of PSA results in many unnecessary prostate biopsies …